High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma
Version of Record online: 19 FEB 2005
Volume 25, Issue 2, pages 266–272, April 2005
How to Cite
Yeo, W., Wong, N., Wong, W.-L., Lai, P. B.S., Zhong, S. and Johnson, P. J. (2005), High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver International, 25: 266–272. doi: 10.1111/j.1478-3231.2005.01084.x
- Issue online: 17 MAR 2005
- Version of Record online: 19 FEB 2005
- Received 27 May 2004, accepted 3 September 2004
- liver cancer tissues;
- promoter methylation;
Abstract: Purpose: To determine the presence of ras association domain family 1A (RASSF1A) promoter methylation in the tumor tissues and plasma of patients with hepatocellular carcinoma (HCC).
Experimental Design: Methylation-specific polymerase chain reaction was used to detect RASSF1A methylation in DNA extracted from HCC tumors and paired plasma samples of 40 patients. The association of RASSF1A hypermethylation in tumor and plasma DNA of HCC patients with clinicopathological characteristics was also analyzed.
Results: RASSF1A promoter hypermethylation was detected in 37 of the 40 HCC tissues (92.5%). Of the paired plasma from the 40 HCC patients, aberrant methylation was detected in 17 (42.5%). No RASSF1A methylation was detected in the plasma in the absence of methylation in the corresponding tumor. The presence of RASSF1A promoter hypermethylation in plasma DNA was found to associate with HCC size of ≥4 cm (P=0.035).
Conclusion: RASSF1A promoter hypermethylation occurred at a high frequency in HCC. The aberrant methylation was also detectable in over 40% of matched plasma. The latter should be evaluated as a screening tool and/or prognosticator of HCC patients.